You can post a question only up to 7 days from the date of the webinar.
You can continue to post comments and stay informed, compliant, and profitable.
Close
This session has expired.
Register for our upcoming webinars & continue to get coding, compliance & reimbursement updates.
Close

Post

Vote
0
0 Followers Follow
Posted By mary peabody on 06-01-2019, 20:40:18 in Ob-Gyn
Hello,

In the table of risk, how can a coder determine if a drug therapy requires intensive monitoring for toxicity? What should be documented by the provider?
Comments (1)
Posted By Melanie Witt on 06-04-2019, 15:13:27
Palmetto has a really good article on this topic: https://www.palmettogba.com/palmetto/providers.nsf/DocsCat/Providers~JM%20Part%20B~EM%20Help%20Center~General%20Articles~8EELEJ7715

I think this information would make a good guide for the need for intensive monitoring. Documentation has to be more than the drug name. The provider should document why intensive monitoring is required for this particular patient. Once the patient is stable this element would not longer apply.
Do you want to remove this attachment from this post?
Yes No
Do you want to add this specialty to your selected specialty list?
Yes No
To comment, please register for any of our webinars. Click here to register for our upcoming webinars.
Close
This comment will be permanently deleted. Do you still want to continue?
Yes No
Do you want to remove this comment from this discussion?
Yes No
Do you want to block this user from participating in this discussion?
Yes No
Do you want to allow this user to participate in this discussion?
Yes No
This post will not be available for further discussion/comments if deleted. Do you still want to continue?
Yes No